This study was the first study to identify the cell surface of GRP94 as a novel potential therapeutic target in cetuximab-resistant CRC, and also to show that the antibody-based modulation of GRP94 might be, at least in part, helpful in overcoming cetuximab resistance. The gene discussed is HSP90B1; the disease is colorectal carcinoma.